LENZ Therapeutics (NASDAQ:LENZ) versus Dr. Reddy’s Laboratories (NYSE:RDY) Head-To-Head Comparison

LENZ Therapeutics (NASDAQ:LENZ) and Dr. Reddy’s Laboratories (NYSE:RDY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Earnings and Valuation

This table compares LENZ Therapeutics and Dr. Reddy’s Laboratories”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$21.48 million	4.61	-$128.51 million	($4.09)	-0.77
Dr. Reddy’s Laboratories	$329.84 billion	0.03	$308.83 million	$0.37	37.18

Dr. Reddy’s Laboratories has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy’s Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

LENZ Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Dr. Reddy’s Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

Insider and Institutional Ownership

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy’s Laboratories shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy’s Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares LENZ Therapeutics and Dr. Reddy’s Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	N/A	N/A
Dr. Reddy’s Laboratories	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and target prices for LENZ Therapeutics and Dr. Reddy’s Laboratories, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1	2	4	0	2.43
Dr. Reddy’s Laboratories	1	3	2	0	2.17

LENZ Therapeutics presently has a consensus price target of $23.00, indicating a potential upside of 630.16%. Dr. Reddy’s Laboratories has a consensus price target of $492.90, indicating a potential upside of 3,483.42%. Given Dr. Reddy’s Laboratories’ higher probable upside, analysts plainly believe Dr. Reddy’s Laboratories is more favorable than LENZ Therapeutics.

Summary

LENZ Therapeutics beats Dr. Reddy’s Laboratories on 6 of the 11 factors compared between the two stocks.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.